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Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disorder characterized by synovial tissue hyperplasia with infiltration of various inflammatory cells leading to cartilage and bone destruction. 1 Although the pathogenesis of RA is still not well understood, two distinct pathways have been identified. The first involves an abnormal synoviocyte-dependent synovial proliferation process while the second is a T cell-and/or macrophage-dependent abnormal immune response. 2 These pathways are not mutually exclusive but rather two intimately related processes. Abnormal proliferation of synoviocytes is, however, not limitless, and spontaneous remission of synovial proliferation has been observed. [3] [4] [5] We have previously demonstrated that both synoviocytes and lymphocytes in rheumatoid synovium expressed functional Fas/APO-1 (CD95) and that these cells undergo a Fasmediated apoptosis. 5 These findings suggest that Fasmediated apoptosis may play a critical role in the regression of rheumatoid synovium hyperplasia.
Fas is a well known mediator of apoptosis and a type I transmembrane glycoprotein belonging to the tumor necrosis factor receptor (TNF-R)/nerve growth factor receptor (NGF-R) superfamily. 6 This molecule is expressed on various normal and neoplastic cells, 7, 8 Correspondence: K Nishioka, Rheumatology including rheumatoid synoviocytes. 3, 5 Fas ligand (FasL), the natural ligand for Fas, is a type II transmembrane glycoprotein homologous to the TNF superfamily. 9 This molecule is expressed on activated T cells and natural killer (NK) cells and induces apoptotic cell death in target cells expressing functional Fas antigen. [10] [11] [12] We previously established mice carrying human T cell leukemia virus type 1 (HTLV-1) representing one of the most suitable animal models of human RA. 13 Using this model, we have recently demonstrated that intra-articular administration of anti-Fas MAb improved the paw swelling and histological features of arthritis by induction of apoptosis of both synoviocytes and mononuclear cells in the inflamed synovium.
14 These findings clearly suggest that apoptosis via the Fas/FasL system may be an important factor for regression of proliferative rheumatoid synovium and administration of anti-Fas MAb could be a novel therapeutic strategy for RA.
Although the use of anti-Fas MAb was limited to the affected joints in the above studies, nevertheless, anti-Fas MAb or soluble FasL may be toxic and cause serious systemic side-effects, such as lethal hepatic injury. 15, 16 In addition, it is not easy to prepare the chimeric type of anti-Fas MAb that avoids host immune responses. Using an alternative approach, we examined in the present study the effect of Fas-mediated apoptosis of proliferative rheumatoid synovium by cells transferred with human FasL (hFasL) gene through cell-to-cell interaction. This was based on the fact that the predominant source of FasL is activated T cells or NK cells under physiological conditions. For this purpose, a murine T lymphoma cell line (L5178Y) transfected with hFasL gene (hFasL/L5178Y) or empty vector alone (mock/L5178Y) were used. 17 hFasL transfectants induced apoptosis of cultured synoviocytes from RA patients via the Fas/FasL system. Furthermore, we injected irradiated-hFasL transfectants into the engrafted human rheumatoid synovium of mice with severe combined immunodeficiency (SCID-RA). This SCID-RA system is considered to be a suitable animal model of human rheumatoid synovium. 18 The injected hFasL transfectants induced apoptosis and regression of the engrafted human rheumatoid synovium. Our results strongly suggest that ex vivo gene transfer of FasL may be useful in the development of an effective therapy for human RA.
Results
Apoptotic effects of hFasL transfectants on cultured rheumatoid synoviocytes via the Fas/FasL system To characterize the functional properties of hFasL transfectants in vivo, we first examined the cytotoxic activity of hFasL transfectants against cultured synoviocytes obtained from patients with RA or osteoarthritis (OA). hFasL cDNA was prepared by reverse transcriptase-polymerase chain reaction (RT-PCR) from total RNA of activated human T cell clone (4HM1), transferred into the BCMGSneo expression vector, 19 and introduced into a murine T lymphoma cell line (L5178Y) which does not express Fas. 10, 17, 20 At the same time, we used control mock transfectants (mock/L5178Y), prepared by transferring empty vector alone into L5178Y. 17 Flow cytometry analysis showed that hFasL transfectants expressed a high level of hFasL. 17 As shown in Figure 1a , hFasL transfectants exhibited cytotoxicity against cultured RA synoviocytes in a dose-dependent manner for 24 h but not against OA synoviocytes although the level of cell surface expression of Fas antigen was similar in both types of synoviocytes. Mock transfectants did not show any cytotoxicity against RA or OA synoviocytes (Figure 1a ). In addition, these transfectants also did not show any cytotoxicity against cultured normal synoviocytes (data not shown). These observations indicated a selective cytotoxicity of hFasL transfectants against RA synoviocytes.
To investigate whether the cytotoxic effects of hFasL transfectants on RA synoviocytes is due to the Fas/FasL system, we performed inhibition assay of hFasL trans- fectant-induced cytotoxicity using neutralizing MAb against Fas (ZB-4) or FasL (NOK-1). As shown in Figure  1b , ZB-4 and NOK-1 inhibited approximately 73 and 90% of RA-specific cytotoxicity of hFasL transfectants, respectively. On the other hand, isotype-matched control Ab did not influence the cytotoxic effect of hFasL transfectants. These results indicate that hFasL transfectants produce selective apoptosis of RA synoviocytes via the Fas/FasL system in vitro.
To characterize further the cytotoxic properties of hFasL transfectants, we examined the apoptotic effect of soluble hFasL in the culture supernatant of hFasL transfectants on cultured RA synoviocytes. The culture supernatant of hFasL transfectants after 3 days culture did not show any cytotoxicity against cultured RA synoviocytes for 24 h (Figure 1c ). This finding indicates that the apoptotic effect of hFasL transfectants on RA synoviocytes is due to cell-to-cell interaction via the cell membranebound FasL but not via the soluble FasL.
Histopathological and immunohistochemical effects of hFasL transfectants on engrafted rheumatoid synovium of SCID-RA mice in vivo To examine the effects of hFasL transfectants on the rheumatoid synovium in vivo, we injected irradiated-transfectants locally in SCID-RA mice engrafted with human rheumatoid synovium. Immunohistochemical examination showed that the injected transfectants, Thy1.2-positive cells, were disseminated in the engrafted human rheumatoid synovium of SCID-RA mice ( Figure 2 ). Histological examination of control SCID-RA mice showed morphological features typical of rheumatoid synovitis including erosion of bone and cartilage, formation of pannus-like granulation tissue, proliferation of synoviocytes and infiltration of various inflammatory cells ( Figure 3a) . In contrast, most synoviocytes and mononuclear cells disappeared in synovia treated with irradiated-hFasL transfectants after 7 days of injection (Figure 3c and d) . Ex vivo injection of irradiated-mock transfectants failed to produce histological changes (Figure 3b ). In addition, polymorphocytes including neutrophils were not observed clearly in the engrafted human RA synovium of SCID-RA mice after injection of hFasL transfectants (data not shown). Therefore, injection of hFasL transfectants did not cause the recruitment of neutrophils and subsequent neutrophil-mediated killing action against the engrafted human RA synovium. Thus, elimination of cells by hFasL transfectants injected locally in the SCID-RA mice was due to apoptosis via the Fas/FasL system by cell-to-cell interaction. Interestingly, hFasL transfectants did not induce any histological changes in mouse tissues surrounding the human rheumatoid synovium (data not shown). These findings strongly suggest that ex vivo injection of irradiated-hFasL transfectants results in the disappearance of almost all synoviocytes and mononuclear cells thus confirming the therapeutic effect of FasL gene transfer in arthritis.
The results of immunohistochemical studies showed that the majority of mononuclear cells in the control engrafted human rheumatoid synovium were mainly CD3 + T cells ( Figure 4a ) and a few CD20 + B cells ( Figure  3b ). CD68
+ macrophages and macrophage-like synoviocytes were also observed in the same engrafted synovium (Figure 4c ). Ex vivo injection of irradiated-hFasL transfectants for 7 days results in almost complete disappearance of CD3 
100). Note proliferation of synovial fibroblasts and infiltration of mononuclear cells. (b) Effect of ex vivo injection of irradiated-mock transfectants on engrafted RA synovium in SCID mice (× 100). No remarkable histological changes were observed. (c) Effect of ex vivo injection of irradiated-hFasL transfectants on engrafted RA synovium in SCID mice (× 100). (d) Effect of ex vivo injection of irradiatedhFasL transfectants on engrafted RA synovium in SCID mice (× 200). Note the dramatic disappearance of synoviocytes and mononuclear cells after 7 days of injection. Data are representative of three individual experiments.
engrafted human rheumatoid synovium strongly expressed Fas antigen (Figure 4d ).
Induction of apoptosis by hFasL transfectants in engrafted rheumatoid synovium of SCID-RA mice in vivo To confirm that the effect of hFasL transfectants on synovial tissue components in SCID-RA mice was due to apoptosis of the cells of engrafted rheumatoid synovium, we examined DNA fragmentation of engrafted rheumatoid synovium by TUNEL method. As shown in Figure  5a , several TUNEL-positive cells were present in engrafted human rheumatoid synovium treated with irradiated-hFasL transfectants, whereas no apoptotic cells were present in synovia treated with irradiated-mock transfectants (Figure 5b ). These results confirm that elimination of mononuclear cells, macrophages and synoviocytes by hFasL transfectants injected locally in the SCID-RA model was due to apoptosis via the Fas/FasL system.
Discussion
There are two major pathogenic processes involved in the development of rheumatoid arthritis; the first is a synoviocyte-dependent process that promotes abnormal proliferation of synoviocytes, while the second is a T celland/or macrophage-dependent abnormal immune response. 2 These pathways are not mutually exclusive and may be intimately related processes subject to a variety of regulatory mechanisms. Admittedly, the true cause of abnormal synovial proliferation is still not well understood.
Recent studies from our group and other laboratories have demonstrated that synoviocytes and lymphocytes in the rheumatoid synovium express functional Fas antigen and undergo apoptosis in vitro and in vivo. 1,3,5 Thus, apoptosis seems to limit abnormal proliferation of synoviocytes and, consequently, enhances spontaneous regression. [3] [4] [5] This process is unique to RA since Fas ligation fails to induce apoptosis in osteoarthritis (OA) despite the expression of Fas antigen on the surface of synoviocytes at levels comparable with those on RA synoviocytes. 3 More recently, we have also reported that Fas ligation selectively induces a rapid tyrosine phosphorylation of JNK (c-Jun amino-terminal kinase) and formation of AP-1 (activator protein-1) corresponding with apoptosis of RA synoviocytes. 21 These observations strongly indicated that Fas-mediated apoptosis is a phenomenon specific to the rheumatoid synovium and involved in the regression of synovial proliferation. Based on these findings, we postulated that active induction of apoptosis in proliferative rheumatoid synovium may be useful as a new mode of therapy for RA. 14 In support of our hypothesis, we have recently demonstrated that intra-articular administration of anti-Fas mAb in the human T cell leukemia virus type 1 (HTLV-1) carrying mice, which was established by our group as a suitable model of human RA, improved the paw swelling and histologic features of arthritis by inducing apoptosis of synoviocytes and mononuclear cells in the inflamed synovium.
14 In contrast, administration of antiFas mAb or soluble FasL in mice was cytotoxic to other Fas-bearing tissues such as the liver, and induced fulminant hepatitis. 15, 16 While the above results provide strong support for a potential therapeutic use of RA synoviocyte apoptosis-inducing agents, they also indicate that further 
Figure 4 Immunohistochemical analysis of the effects of hFasL transfectants on engrafted human rheumatoid synovium of SCID-RA mice. (a-d) Human RA synovium in SCID mouse treated with irradiated-mock transfectants for 7 days (× 200). (e-h) Human RA synovium in SCID mouse treated with irradiated-hFasL transfectants for 7 days (× 200). Each panel shows immunohistochemical study, using MAbs against CD3 (a and e), CD20 (b and f), CD68 (c and g) and Fas (d and h). The number of CD3, CD20, CD68, and Fas-positive cells were clearly reduced in synovium treated with irradiatedhFasL transfectants relative to control mouse. Data are representative of three individual experiments.
studies are needed to examine possible side-effects of such agents, including possible leakage of anti-Fas MAb or soluble FasL administered intra-articularly into the systemic circulation. In addition, it is not easy to prepare chimeric anti-Fas MAb of murine F(ab) with human Fc portions that avoid a host immune response against MAb. Thus, considering the potential accumulation, safety, and physiological conditions for recruitment of FasL, we used cells transfected with hFasL gene in the present study to examine the potential induction of apoptosis in proliferative rheumatoid synovium through cell-to-cell interaction, since FasL-positive activated T cells and natural killer (NK) cells play an important role in the induction of apoptosis under physiological conditions.
In the first series of experiments, we showed that hFasL transfectants induced apoptosis of cultured RA synoviocytes by cell-to-cell interaction via the Fas/FasL system. To confirm our in vitro results in the human in vivo system, we used mice with severe combined immunodeficiency (SCID). Recent studies have demonstrated that the SCID mouse has several defects in both humoral and cellmediated immunity, and can serve as a recipient of grafts derived from a variety of human tissues, [22] [23] [24] [25] [26] [27] including rheumatoid synovium. Thus, proliferative rheumatoid synovium can grow as a xenograft in SCID mice and pre- serve the histologic components of rheumatoid synovia. 18 In addition, engraftment of human rheumatoid synovium into the knee joint of SCID mice can cause arthritis 28 and the implant can reproduce the biologic characteristics of destruction of the normal cartilage of humans. 29 Engraftment of human rheumatoid synovium into the back muscle of SCID mice (SCID-RA) also preserved the histologic components of rheumatoid synovia. In our approach using gene therapy for RA employing the SCID-RA system, we showed that local injection of irradiated-hFasL transfectants resulted in elimination of Fas-positive synoviocytes, CD3 + , CD20
+ and CD68 + cells from the rheumatoid synovium due to the induction of apoptosis without any extra immune response by xenotransplantation or bystander cytotoxicity of transfectants against host tissues.
Another approach using gene therapy for RA, by manipulating cytokine regulation, has recently been discussed. Several recent studies have been successful in introducing genes into the synovium of the knee joints of rabbits by both ex vivo 30, 31 and in vitro 32, 33 methods. One potentially therapeutic gene encoding the human interleukin-1 (IL-1) receptor antagonist has been tested in some detail. Ex vivo transfer of human IL-1 receptor antagonist gene using retrovirus, MFG-IRAP, resulted in intraarticular accumulation of human IL-1 receptor antagonist and inhibited the inflammatory effects of locally injected IL-1␤. 31 While this approach is promising, it is clear that in joint lesions of human RA, there is not only an imbalance of certain proinflammatory cytokines, such as IL-1␤, but also disturbances of apoptotic mechanisms such as the Fas/FasL system. Thus, it appears that the Fas/FasL system does not operate perfectly in removing all Faspositive proliferative synoviocytes and mononuclear cells in the rheumatoid synovium, leading to the development of a chronic inflammatory state, although FasL is expressed on activated T cells and NK cells such as CD4 + , CD8
+ and CD56 + cells. 34 Overexpression of soluble Fas antigen in synovial fluid of RA patients may be one factor responsible for disturbances of Fas/FasL-mediated apoptosis. 35 Therefore, active transfer of FasL-positive cells into the joint space may by itself inhibit proliferative RA, as FasL transfectants induce Fas/FasL-mediated apoptosis of proliferative synoviocytes and autoreactive T cells in rheumatoid synovium.
In conclusion, our findings indicated that ex vivo injection of cells transfected with hFasL gene induced apoptosis in proliferative rheumatoid synovium. These results strongly suggest that FasL gene transfer may provide a beneficial therapeutic effect in patients with RA. Recently, Seino et al 36 showed that cells transfected with hFasL gene have potent antitumor properties due to neutrophil-mediated primary rejection and subsequent CD8 + T cell-mediated protective immunity. These results suggest that gene transfer of FasL might be an effective therapeutic strategy against cancer. Thus, the Fas/FasL system may be involved in the pathogenesis and natural history of various diseases. Establishment of autologous T cells transfected with hFasL gene will help in further refining the possible clinical use of gene therapy for RA.
Materials and methods

Cell culture
Patients with RA were diagnosed according to the criteria of the American College of Rheumatology (ACR, formerly ARA) 37 while patients with OA were diagnosed based on clinical criteria. Following informed consent, synovial tissue samples were obtained from five RA patients and three OA patients. Cultured synovial cell lines were established as described previously. 38 Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (GIBCO BRL, Grand Island, NY, USA) supplemented with 10% fetal calf serum (FCS) (GIBCO) until examination. Transfectants (hFasL/L5178Y and mock/L5178Y) were kindly provided by Professor K Okumura (Juntendo University, Tokyo, Japan) and previously described. 17 The transfectants were cultured in RPMI 1640 containing 10% FCS.
Antibodies
For inhibition analysis, we used anti-Fas monoclonal antibody (MAb) representing no killing activity (ZB-4) (Medical & Biological Laboratory, Nagoya, Japan) and anti-FasL MAb representing no killing activity (NOK-1), 17 kindly provided by Professor K Okumura. For immunohistochemical analysis, we used MAbs against Thy1.2, CD3, CD20, CD68 (Dako, Kyoto, Japan) and Fas (Medical & Biological Laboratory).
Cytotoxicity assay
Briefly, synovial cell lines were seeded in 48-well plates at 2 × 10 4 cells per well. Five RA and three OA synovial cell lines from different patients were used for further experiments. After 24 h, the cells were pretreated with anti-Fas neutral MAb (ZB-4; at a final concentration of 1 g/ml), anti-FasL neutral MAb (NOK-1; at a final concentration of 1 g/ml), medium alone, or isotypematched control Ab. The cells were then cocultured with transfectants (hFasL/L5178Y or mock/L5178Y) at the indicated effector cells/target cells ratio (E/T ratio). To test the cytotoxic activity of soluble hFasL released from hFasL transfectants, hFasL transfectants were cultured for 3 days at 2 × 10 4 cells per well. Then, RA synovial cell lines were cultured with the culture supernatant of hFasL transfectants at the indicated E/T ratio. After 24 h, the colorimetric LDH-release assay was performed according to the instructions provided by the manufacturer (Promega, Madison, WI, USA), and absorption values were determined at 490 nm with an automatic microtiter plate reader.
SCID-RA mice SCID mice engrafted with human rheumatoid synovium were prepared as described previously. 18 Briefly, after joint surgery, the human tissue specimen was quickly grafted into male SCID mice aged 6 to 7 weeks (CB.17/lcr) (SLC, Tokyo, Japan). All mice were kept and handled under specific pathogen-free conditions. Mice were anesthetized with inhalation of diethylether. A 1 cm incision was made in the middle of the back and paravertebral muscle was exteriorized. The back muscle was incised and a 1 cm 3 mixture of human synovium and joint cartilage cut into small pieces was mixed together. The entire procedure was performed under sterile conditions. Using this approach, the overall recovery rate was 100%. The transfectants (hFasL/ L5178Y or mock/L5178Y) were irradiated (70 Gy) and injected at 1 × 10 7 cells into the engrafted location in these mice. The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation.
Histopathological and immunohistological analyses
After injection of irradiated-transfectants (hFasL/L5178Y or mock/L5178Y) into SCID-RA, human rheumatoid synovium including joint cartilage were fixed in 10% formalin neutral buffer solution and decalcified in EDTA/formalin solution. The tissue samples were then embedded in paraffin, sectioned, mounted on to glass slides, and used for further examination. For histopathological analysis, the sections were stained with hematoxylin and eosin (H-E). For immunohistological analysis, the sections were blocked with 1.5% normal serum for 30 min at room temperature and then incubated with MAbs against Thy1.2, CD3, CD20, CD68 and Fas. The samples were then treated with biotinylated second Ab for 15 min at room temperature. Visualization was performed using Catalyzed Signal Amplification System (Dako).
DNA nick end labeling (TUNEL) analysis
Samples of human rheumatoid synovium including joint cartilage were fixed in 10% formalin neutral buffer solution and decalcified in EDTA/formalin solution. The tissue specimens were then embedded in paraffin, sectioned, mounted on to glass slides, and used for further experiments. Fragmented DNA was detected by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) method described previously. 39 Briefly, the sections were immersed in TdT buffer containing 30 mm Tris-HCl, pH 7.2, 140 mm sodium cacodylate and 1 mm cobalt chloride. TdT (GIBCO BRL) and biotinylated dUTP (Boehringer Mannheim, Indianapolis, IN, USA) were added to the samples. The reaction was terminated by immersing in TB buffer containing 300 mm sodium chloride and 30 mm sodium citrate. Samples were then treated with peroxidase-labeled streptavidin and visualized by VECTASTAIN ABC kit (Vector Laboratories, Burlingame, CA, USA).
